Fusion Pharmaceuticals Inc.
Clinical trials sponsored by Fusion Pharmaceuticals Inc., explained in plain language.
A clinical-stage biotech developing targeted alpha-particle therapies for cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the treatment can shrink tumors or lower PSA levels by at least 50%. Participants must have tried at …
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for tough prostate cancer: targeted radiation drug enters phase 2 trial
Disease control OngoingThis study tests a new radioactive drug, FPI-2265, in 110 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy. Participants must have already received a similar radioactive treatment. The goal is to find the safest d…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Targeted radiation shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial tests a drug called FPI-2265, which delivers targeted radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The study will measure how w…
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC